Abstract
Retroperitoneal soft tissue sarcomas mainly consist histologically of liposarcomas
and leiomyosarcomas. For the liposarcoma subgroup, the local relapse rate seems to
determine patients' overall prognosis. In contrast, leiomyosarcoma patients are challenged
by the development of metastatic disease; therefore, effective systemic therapies
are the cornerstone to improve patients’ outcome. No doubt, the limited number of
active regimens currently available makes the treatment of patients with locally advanced
and/or metastatic disease challenging and results in the overall poor prognosis of
this population. In this European Journal of Surgical Oncology Educational Special Issue from the Transatlantic Australasian RetroPeritoneal Sarcoma
Working Group (TARPSWG), we aim to summarize state-of-the-art systemic treatments
for patients with retroperitoneal sarcomas with a focus on the locally advanced and
metastatic disease setting including conventional standard chemotherapies as well
as new innovative treatment approaches in order to identify current unmet medical
needs guiding the sarcoma community to initiate appropriate translational research
projects and design innovative clinical trials.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Surgical OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- World Health Organization (WHO) classification of soft tissue and bone tumours. fifth ed. International Agency for Research on Cancer (IARC), Lyon2020
- ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2021; https://doi.org/10.1016/j.annonc.2021.07.006
- Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2020; 21: 1366-1377
- Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.Lancet Oncol. 2017; 18: 812-822
- Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and polish (PSG) sarcoma groups.J Clin Oncol. 2020; 38: 2178-2186
- Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: a multi-institutional study from the transatlantic Australasian retroperitoneal sarcoma working group.Cancer. 2021; 127: 729-738
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.Lancet Oncol. 2014; 15: 415-423
- First-line chemotherapy in advanced well differentiated/dedifferentiated liposarcoma (WD/DD LPS): an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.Ann Oncol. 2020; 31: S914-S933
- Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).Eur J Cancer. 2010; 46: 72-83
- Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.Cancer. 2020; 126: 2637-2647
- Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.Lancet Oncol. 2015; 16: 457-464
- LMS-04 study: a randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients, as first-line therapy in patients with metastatic or unresectable leiomyosarcoma - a French Sarcoma Group study.Ann Oncol. 2021; 32: S1283-S1346
- Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.J Clin Oncol. 2009; 27: 4188-4196
- Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial.J Clin Oncol. 2016; 34: 786-793
- Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.Ann Oncol. 2013; 24: 1703-1709
- Impact of pathological stratification on the clinical outcomes of advanced wee-differentiated/dedifferentiated liposarcoma treated with trabectedin.Cancers (Basel). 2021; 13: 1453
- Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.Lancet. 2016; 387: 1629-1637
- Eribulin versus dacarbazine in advanced leiomyosarcoma: subgroup analysis from a phase 3 open-label randomized study.Br J Cancer. 2019; 120: 1026-1032
- Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine.J Clin Oncol. 2017; 35: 3433-3439
- Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.J Clin Oncol. 2011; 29: 2528-2533
- Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].J Clin Oncol. 2007; 25: 2755-2763
- Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).Oncol. 2012; 17: 1213-1220
- A pooled analysis of the final results of two randomised phase II studies comparing gemcitabine vs. gemcitabine plus docetaxel in patients with metastatic/relapsed leiomyosarcoma.in: Presented at the 16th annual meeting of the connective tissue Oncology society. CTOS, Paris2010
- Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.Lancet Oncol. 2017; 18: 1397-1410
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.Lancet. 2012; 379: 1879-1886
- A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma.Clin Sarcoma Res. 2015; 5: 13
- Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.Cancer. 2019; 125: 2610-2620
- High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma.Clin Sarcoma Res. 2014; 4: 16
- Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.J Clin Oncol. 2013; 31: 2024-2028
- Progression-free survival Among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial.JAMA Oncol. 2016; 2: 937-940
- Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma.J Clin Oncol. 2019; 37
- MDM2-master regulator of the p53 tumor suppressor protein.Gene. 2000; 242: 15-29
- Effect of the MDM2 antagonist RG7112 on the p53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof of mechanism study.Lancet Oncol. 2012; 13: 1133-1140
- A phase I study of SAR405838, a novel human double minute 2 (MDM2) antagonist in patients with solid tumors.Eur J Cancer. 2017; 76: 144-151
- Phase I trial of the human double minute 2 inhibitor MK-8242 in patients with advanced solid tumors.J Clin Oncol. 2017; 35: 1304-1311
- Milademetan, an oral MDM2 inhibitor in well-differentiated/dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumor and lymphomas.in: 32nd EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics - abstract Book. Eur J Cancer. vol. 138. 2020 (S2, S3: Abs 7LBA)
- Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma.J Clin Oncol. 2016; 34: 3166-3174
- Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: a phase 2/3, randomized, double blind, placebo controlled cross-over study.J Clin Oncol. 2018; 36
- A phase 2/3, randomized, double blind, crossover, study of Selinexor versus placebo in advanced unresectable de-differentiated liposarcoma (DDLS).in: Presented at the virtual annual meeting of the connective tissue Oncology society. CTOS, 2020
- Updated results of European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 1202 cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma.J Clin Oncol. 2021; 39 (abstr 11518)
- Integrative genomic and transcriptomic analysis of leiomyosarcoma.Nat Commun. 2018; 9: 144
- PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.Mol Cancer. 2017; 16: 86
- Trabectedin and olaparib in patients with advanced and non-resectable bone and soft tissue sarcoma: an open-label. Phase 1b study from the Italian Sarcoma Group.Lancet Oncol. 2018; 19: 1360-1371
- Phase II trial of pegylated arginine deiminase in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.J Clin Oncol. 2021; 39 (abstr 11508)
- Unmet medical needs and future perspectives for leiomyosarcoma patients - a position paper from the National LeioMyoSarcoma Foundation (NLMSF) and sarcoma patients EuroNet (SPAEN).Cancers (Basel). 2021; 13: 886
- Immune checkpoint inhibitors: the linchpins of modern immunotherapy.Immunol Rev. 2019; 290: 6-23
- PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.J Hematol Oncol. 2020; 13: 55
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.Lancet Oncol. 2017; 18: 1493-1501
- Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study.Cancer. 2017; 123: 3285-3290
- Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.Lancet Oncol. 2018; 19: 416-426
- Use of PD-1 targeting, macrophage infiltration, and IDO pathway Activation in sarcomas: a phase 2 clinical trial.JAMA Oncol. 2018; 4: 93-97
- Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.Lancet Oncol. 2019; 20: 837-848
- T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.Cancer. 2017; 123: 3291-3304
- B cells are associated with survival and immunotherapy response in sarcoma.Nature. 2020; 577: 556-560
- Comprehensive and integrated genomic characterization of adult soft tissue sarcomas.Cell. 2017; 171: 950-965
- Clinical activity of pembrolizumab in undifferentiated pleomorphic sarcoma (UPD) and dedifferentiated liposarcoma (LPS): final results of SARC028 expansion cohort.J Clin Oncol. 2019; 37 (abstr 11015)
- Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.Oncogene. 2010; 29: 845-854
- Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity.Nat Med. 2010; 16 (781-187)
- The Nanocind signature is an independent prognosticator of recurrence and death in uterine leiomyosarcomas.Clin Cancer Res. 2020; 26: 855-861
- Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics.Clin Cancer Res. 2013; 19: 1190-1196
- The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma.Ann Oncol. 2018; 29: 459-465
- Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.Ann Oncol. 2020; 31: 1506-1517
- Proteomic research in sarcomas - current status and future opportunities.Semin Cancer Biol. 2020; 61: 56-70
- Improved survival using specialized multidisciplinary board in sarcoma patients.Ann Oncol. 2017; 28: 2852-2859
- Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma.Cancer. 2018; 124: 4495-4503
Article info
Publication history
Published online: December 30, 2021
Accepted:
December 25,
2021
Received in revised form:
December 20,
2021
Received:
August 25,
2021
Identification
Copyright
© 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
